Abstracts tagged "Cardiovascular disease"

Abstract Number: 39 • 2015 ACR/ARHP Annual Meeting
Baseline Obesity and Subsequent Weight Loss Are Independently Associated with Cardiovascular Mortality in Established Rheumatoid Arthritis
Bryant R. England¹, Joshua F. Baker², Harlan Sayles³, Kaleb Michaud^4,5, Liron Caplan⁶, Lisa A. Davis⁶, Grant W. Cannon⁷, Brian Sauer⁸, E. Blair Solow⁹, Andreas Reimold¹⁰, Gail S. Kerr¹¹, Pascale Schwab¹² and Ted R. Mikuls¹³, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁸Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁰Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹¹VAMC, Georgetown University, Washington, DC, ¹²Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹³Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In the general population, higher body mass index (BMI) is associated with cardiovascular (CV) disease. However, an obesity paradox has been observed in rheumatoid…
Abstract Number: 954 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Osteoarthritis and Cardiovascular Disease: Results from a Population-Based Cohort
Lauren King¹, Tetyana Kendzerska^1,2,3 and Gillian Hawker^1,2,3, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
Background/Purpose: Symptomatic osteoarthritis (OA) and cardiovascular disease (CVD) commonly co-exist. Our aim was to determine the extent to which this relationship is explained by common…
Abstract Number: 1543 • 2015 ACR/ARHP Annual Meeting
Traditional Risk Score Underestimates the Cardiovascular Risk in Rheumatoid Arthritis Patients
Tomas Cazenave¹, Natalia Zamora¹, Gustavo Citera^1,2 and Marcos G. Rosemffet¹, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina
Background/Purpose: An increased incidence of cardiovascular (CV) mortality has been reported in patients with rheumatoid arthritis (RA). Adequate stratification of the CV risk is an…
Abstract Number: 1709 • 2015 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis in Patients with Psoriatic Arthritis and the Role of Vitamin D
Montserrat Robustillo-Villarino¹, Cristina Vergara-Dangond¹, Gloria Albert Espi¹, Marcos Cerqueira², Desamparados Ybañez García¹, Elia Valls¹, Elvira Vicens-Bernabeu¹, Juan José Alegre¹ and Àngels Martínez-Ferrer¹, ¹Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ²Hospital de Ponte de Lima, ULSAM, Department of Rheumatology,Hospital de Ponte de Lima, ULSAM, Ponte de Lima, Portugal
Background/Purpose: Psoriatic arthritis (PsA) is associated with increased cardiovascular risk (CV)[i]. Several studies associate low levels of 25-hydroxivitamin D (25OHD) with a greater prevalence of…
Abstract Number: 2413 • 2015 ACR/ARHP Annual Meeting
Contributors to Walking Disability in People with Osteoarthritis: Results from a Population-Based Cohort
Lauren King¹, Tetyana Kendzerska^1,2,3 and Gillian Hawker^1,2,3, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) is associated with functional limitations, including difficulty walking. However, comorbid disease is common in people with OA and may also be associated…
Abstract Number: 115 • 2015 ACR/ARHP Annual Meeting
Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening
Michael Grasso¹, Dana Direnzo², Yelena Yesha³, Naphtali Rishe⁴ and Amanda Niskar⁵, ¹Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Internal Medicine, University of Maryland Medical Center, Baltimore, MD, ³Computer Science and Electrical Engineering, Professor, Baltimore, MD, ⁴Computer Science, Florida International University, Miami, FL, ⁵1330 West Peachtree Street NW, Arthritis Foundation, Atlanta, GA
Background/Purpose: We extracted a large cohort of rheumatoid arthritis (RA) patients, on which we plan to apply big data analytics for earlier diagnosis of RA.…
Abstract Number: 1057 • 2015 ACR/ARHP Annual Meeting
Are Ankylosing Spondylitis, Psoriatic Arthritis and Undifferentiated Spondylarthritis Associated with an Increased Risk of Cardiovascular Disease?
Karin Bengtsson¹, Helena Forsblad-d'Elia², Elisabeth Lie¹, Eva Klingberg¹, Mats Dehlin¹, Sofia Exarchou³, Ulf Lindström¹, Johan Askling⁴ and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: It is unclear whether and to what extent different phenotypes of spondylarthritis (SpA) are associated with an increased risk of cardiovascular events such as…
Abstract Number: 1547 • 2015 ACR/ARHP Annual Meeting
Implementing an Electronic Medical Recorded-Based Clinical Decision Support Tool Did Not Improve Cardiovascular Risk Screening in Rheumatoid Arthritis Patients
Anand Kumthekar¹, Michail Alevizos², Nicole Jordan³ and Anna R. Broder⁴, ¹Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, ³Montefiore Medical Center, New York, NY, ⁴Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death among individuals with rheumatoid arthritis (RA). The 2010 EULAR guidelines recommend annual CV risk assessment…
Abstract Number: 1787 • 2015 ACR/ARHP Annual Meeting
Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Monica Purmalek¹, Simantini Sakhardande¹, Yenealem Temesgen-Oyelakin², Alice Fike³, Taufiq Salahuddin⁴, Balaji Natarajan⁴, Zerai Manna², Elizabeth Joyal², Sarfaraz Hasni², Nehal N. Mehta⁴ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, compared to…
Abstract Number: 2501 • 2015 ACR/ARHP Annual Meeting
Determining the Rate of Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis at Federally Qualified Outpatient Continuity Clinic – a Performance Improvement Project
Dewan Fahima¹ and Rafah Salloum², ¹Internal Medicine, Monmouth Medical Center, Long Branch, NJ, ²Rheumatology, Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Studies have shown patients with rheumatoid arthritis (RA), a chronic inflammatory condition, have accelerated rate of coronary artery and cerebrovascular disease. Patients with RA,…
Abstract Number: 133 • 2015 ACR/ARHP Annual Meeting
Advocating for Rheumatoid Arthritis and Cardiovascular Health (ARCH) in a Tertiary Referral Center: A Collaborative and Systems-Based Approach to Improve Access to Care
Barbara Goldstein¹, JoAnn Zell¹, Pearlanne Zelarney², Matthew Stern², Sarah Meadows², Meg Dingae², Carmen Egidio² and Darlene Kim², ¹Medicine, National Jewish Health, Denver, CO, ²National Jewish Health, Denver, CO
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD) as compared to the general population. The European League Against Rheumatism…
Abstract Number: 1202 • 2015 ACR/ARHP Annual Meeting
Knowledge and Perception of Cardiovascular Disease Risk in Patients with Psoriatic Disease
Dennis Wong¹, Daniel Pereira², Sutha Shanmugarajah¹, Renise Ayearst², Dafna Gladman², Cheryl Rosen³ and Vinod Chandran², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The prevalence of cardiovascular diseases (CVD) is higher in patients with psoriatic disease. Psoriatic disease is known to be an independent risk factor for…
Abstract Number: 1550 • 2015 ACR/ARHP Annual Meeting
Flares of Disease Activity As Risk Factor for the Occurrence of Myocardial Infarction in Patients with Rheumatoid Arthritis
Esmee Bakker¹, Pauline Geuijen², Beata Radovits¹, Delia Popa-Diaconu¹, Calin Popa¹, Elke Arts¹, Alfons A. den Broeder³ and Jaap Fransen¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). The underlying mechanism is partly explained by the inflammation process in both…
Abstract Number: 1788 • 2015 ACR/ARHP Annual Meeting
Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Simantini Sakhardande¹, Monica Purmalek¹, Maureen Sampson², Yenealem Temesgen-Oyelakim³, Alice Fike⁴, Taufiq Salahuddin⁵, Balaji Natarajan⁵, Zerai Manna⁶, Elizabeth Joyal⁶, Marcus Chen⁵, Sarfaraz Hasni⁶, Nehal N. Mehta^5,7, Alan Remaley⁵ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²CC/NIH, Bethesda, MD, ³Office of the Clinical Director,National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵NHLBI, National Institutes of Health, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Risk of atherosclerotic cardiovascular disease (CVD) is significantly enhanced in systemic lupus erythematosus (SLE) compared to age and gender matched controls. While this risk…
Abstract Number: 2578 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Effects of Etanercept in an Animal Model of Rheumatoid Arthritis: Mechanisms Involved
Perle Totoson¹, Katy Maguin-Gaté¹, Alice Monnier², Anne Tessier², Christine Marie², Frank Verhoeven³, Clément Prati³, Daniel Wendling⁴ and Céline Demougeot¹, ¹EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, ²INSERM U1093, Université de Bourgogne Franche-Comté, Dijon, France, ³Service de Rhumatologie, CHRU J Minjoz, Besançon, France, ⁴Université de Franche-Comté, Besançon, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality secondary to endothelial dysfunction (ED). Growing evidence suggests that TNFα-inhibitors may reduce…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].